CRIS
$0.87+0.01 (+1.41%)
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inh...
Recent News
How The Curis (CRIS) Narrative Is Evolving As Assumptions Shift But The Target Stays
Curis is back in focus as analysts reaffirm a $14.00 per share fair value, holding the line on their headline price target even as they revisit the assumptions underneath it. Rather than moving that $14.00 figure, recent commentary is centering on whether the current target still makes sense given the latest thinking on execution risks, profitability, and valuation support. As you read on, you will see how this updated narrative is evolving and what it could mean for tracking Curis from...
How The Narrative Around Curis (CRIS) Is Shifting As Assumptions Change Not The US$14 Target
Curis is back on investors’ radar after analysts reaffirmed a US$14.00 fair value per share, while quietly adjusting some of the key assumptions that sit behind that number. The discount rate shift to 11.03% and the steady revenue growth outlook of around 43.46% indicate that the story around risk and growth is being fine tuned rather than rewritten. As you read on, keep an eye on how these moving parts shape the evolving narrative around Curis and how you can stay on top of future...
Looking At The Narrative For Curis CRIS After Fresh Funding And Fair Value Reset
The latest update on Curis centers on a refreshed price target that holds fair value at US$14.00 while reshaping the story behind how that figure is reached. Analysts have adjusted the model inputs around revenue growth assumptions of 43.46% and a higher discount rate of 11.93%, reflecting a balance between confidence in longer term earnings power and caution on near term execution risk. As you read on, you will see how this evolving narrative is being built and how you can keep on top of...
How Recent Developments Are Shaping the Curis Investment Story
Curis stock has recently drawn increased attention following the latest round of analyst updates, with the consensus price target holding steady at $14.00 per share. While forecasts show little movement, the slight uptick in Curis’s discount rate signals a nuanced shift in the market’s perception of risk. Stay tuned to learn how investors can track these subtle yet impactful changes in the company’s evolving narrative moving forward. Stay updated as the Fair Value for Curis shifts by adding...
Why Analysts Are Rethinking Curis After Nasdaq Warning and Price Target Drop
Curis stock has recently seen its consensus analyst price target decline from $16.33 to $14.00, marking a notable downward revision in its perceived fair value. This shift comes as analyst sentiment changes while they assess the company’s growth prospects and execution in relation to broader market concerns. Stay tuned to learn how you can closely follow the evolving narrative and analyst expectations surrounding Curis stock. Analyst Price Targets don't always capture the full story. Head...